BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2020

Jan 17, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2020-01-08

Reporting Person: Jones Michael L (Exec Director, Finance - PAO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	848	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Emp. Stock Option (Right to Buy)	$3.51	2021-03-21	Common Stock (4500)		Direct
Emp. Stock Option (Right to Buy)	$4.73	2022-03-01	Common Stock (2300)		Direct
Emp. Stock Option (Right to Buy)	$1.42	2023-01-01	Common Stock (8600)		Direct
Emp. Stock Option (Right to Buy)	$5.45	2023-08-08	Common Stock (10000)		Direct
Emp. Stock Option (Right to Buy)	$10.80	2024-01-20	Common Stock (2700)		Direct
Emp. Stock Option (Right to Buy)	$12.16	2025-01-01	Common Stock (3200)		Direct
Emp. Stock Option (Right to Buy)	$10.82	2025-12-29	Common Stock (3666)		Direct
Emp. Stock Option (Right to Buy)	$3.22	2026-05-23	Common Stock (7584)		Direct
Emp. Stock Option (Right to Buy)	$11.13	2024-12-22	Common Stock (4200)		Direct
Emp. Stock Option (Right to Buy)	$5.51	2027-02-27	Common Stock (6000)		Direct
Emp. Stock Option (Right to Buy)	$5.04	2027-12-20	Common Stock (3250)		Direct
Emp. Stock Option (Right to Buy)	$7.06	2028-12-20	Common Stock (18000)		Direct
Emp. Stock Option (Right to Buy)	$3.23	2029-12-17	Common Stock (22000)		Direct

Footnotes

F1: Options become exercisable at a rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.